CMA doles out £100 million in fines for excessive pricing of thyroid drug

The UK’s Competition and Markets Authority has hit Advanz Pharma and its two former owners with more than £100 million in fines for overcharging the country’s national health service for thyroid medication liothyronine over an eight-year period.


Get unlimited access to all Global Competition Review content